These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prolongation of verapamil elimination kinetics during chronic oral administration. Schwartz JB; Keefe DL; Kirsten E; Kates RE; Harrison DC Am Heart J; 1982 Aug; 104(2 Pt 1):198-203. PubMed ID: 7102502 [TBL] [Abstract][Full Text] [Related]
4. Systemic availability of oral verapamil and effect on PR interval in man. Johnston A; Burgess CD; Hamer J Br J Clin Pharmacol; 1981 Sep; 12(3):397-400. PubMed ID: 7295469 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of verapamil in patients with renal failure. Mooy J; Schols M; v Baak M; v Hooff M; Muytjens A; Rahn KH Eur J Clin Pharmacol; 1985; 28(4):405-10. PubMed ID: 4029246 [TBL] [Abstract][Full Text] [Related]
6. Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration. Asthana OP; Woodcock BG; Wenchel M; Frömming KH; Schwabe L; Rietbrock N Arzneimittelforschung; 1984; 34(4):498-502. PubMed ID: 6540109 [TBL] [Abstract][Full Text] [Related]
7. Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. Busse D; Fromm MF; Mörike K; Drescher S; Kühlkamp V; Eichelbaum M Clin Pharmacol Ther; 2001 May; 69(5):324-32. PubMed ID: 11372000 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of calcium channel blocking agents. Anderson P Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():43-57. PubMed ID: 2940799 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. Woodcock BG; Wörner P; Rietbrock N; Schwabe L; Frömming KH Arzneimittelforschung; 1982; 32(12):1567-71. PubMed ID: 6891597 [TBL] [Abstract][Full Text] [Related]
11. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. McAllister RG; Kirsten EB Clin Pharmacol Ther; 1982 Apr; 31(4):418-26. PubMed ID: 7060323 [TBL] [Abstract][Full Text] [Related]
12. Physiological disposition of verapamil in man. Schomerus M; Spiegelhalder B; Stieren B; Eichelbaum M Cardiovasc Res; 1976 Sep; 10(5):605-12. PubMed ID: 971476 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of verapamil in patients with hypertension. Anderson P; Bondesson U; de Faire U Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414 [TBL] [Abstract][Full Text] [Related]
14. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. Piotrovskii VK; Rumiantsev DO; Nikolenko SA; Riabokon OS; Metelitsa VI Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):4-11. PubMed ID: 3957489 [TBL] [Abstract][Full Text] [Related]
15. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. Hong SP; Chang KS; Koh YY; Choi DH; Choi JS Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of verapamil in man. Koike Y; Shimamura K; Shudo I; Saito H Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):37-47. PubMed ID: 432439 [TBL] [Abstract][Full Text] [Related]
17. Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats. Todd EL; Abernethy DR Biopharm Drug Dispos; 1987; 8(3):285-97. PubMed ID: 3593905 [TBL] [Abstract][Full Text] [Related]